Alpine Immune Sciences, Inc.

Rentabilité sur six mois: 0%
Rendement en dividendes: 0%
Secteur: Healthcare

7.7 $

0 $ 0%
7.5 $
64.97 $

paper.min_max_per_year

Calendrier des promotions Alpine Immune Sciences, Inc.

À propos de l'entreprise Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

Paramètres de base

IPO date
2015-06-17
ISIN
US02083G1004
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт

Grade

Sous-estimation
Nom Signification Grade
P/S 16.49 1
P/BV 2.96 6
P/E 0 0
Efficacité
Nom Signification Grade
ROA -8.43 0
ROE -9.81 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.227 10
Debt/Ratio 0.026 10
Debt/Equity 0.1643 10
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 3363.29 10
Rentabilité Ebitda, % 5.24 1
Rentabilité EPS, % -72.26 0

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 7.7 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.7d 7.7 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.30d 7.7 $ 7.7 $ 7.7 $ 0 % 0 % 0 %
common.calendar.number_days.90d 7.7 $ 7.7 $ 7.7 $ 0 % 0 % 0 %
common.calendar.number_days.180d 7.7 $ 7.7 $ 7.7 $ 0 % 0 % 0 %
common.calendar.number_days.1y 7.7 $ 7.5 $ 64.97 $ 0 % 0 % 0 %
common.calendar.number_days.3y 8 $ 5.45 $ 64.97 $ -3.75 % 0 % 0 %
common.calendar.number_days.5y 10.5 $ 5.45 $ 64.97 $ -26.67 % 0 % 0 %
common.calendar.number_days.10y 2.04 $ 2.04 $ 64.97 $ 377.45 % 0 % 0 %
common.calendar.number_days.ytd 7.7 $ 7.7 $ 7.7 $ 0 % 0 % 0 %

Principaux propriétaires

Entreprises similaires



Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Dr. Mitchell H. Gold M.D. Executive Chairman & CEO 1.02M 1968 (57 années)
Dr. Stanford Peng M.D., Ph.D. President and Head of Research & Development 940.1k 1971 (54 année)
Mr. Paul Rickey Senior VP, CFO, Treasurer & Secretary 691.1k 1979 (46 années)
Dr. Remy Durand Ph.D. Chief Business Officer N/A 1985 (40 années)
Ms. M. Christina Yi Chief Technology Officer N/A 1977 (48 années)
Temre Johnson Head of IR & Corporate Communications
Dr. Wolfgang Dummer M.D., Ph.D. Chief Medical Officer 1966 (59 années)

Informations sur l'entreprise

Adresse: United States, Seattle. WA, 188 East Blaine Street - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.alpineimmunesciences.com